二苯特罗 | 14587-50-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 二苯特罗
• 英文名称: difeterol
• 英文别名: 2-[2-benzhydryloxyethyl(methyl)amino]-1-phenylpropan-1-ol
• CAS: 14587-50-9
• 化学式: C₂₅H₂₉NO₂
• 分子量: 375.511
• InChiKey: OEHKWMHRFWWMQK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  32.7
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2922509090

文献信息

• Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
  申请人：Scaramuzzino, Giovanni

  公开号：EP1336602A1

  公开（公告）日：2003-08-20

  New pharmaceutical compounds of general formula (I): F-(X)q where q is an integer from 1 to 5, preferably 1; -F is chosen among drugs described in the text, -X is chosen among 4 groups -M, -T, -V and -Y as described in the text. The compounds of general formula (I) are nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without hypotensive side effects and for this reason they are useful for the preparation of medicines for prevention and treatment of inflammatory, ischemic, degenerative and proliferative diseases of musculoskeletal, tegumental, respiratory, gastrointestinal, genito-urinary and central nervous systems.

  通式（I）的新药物化合物：F-（X）q，其中q是1到5的整数，最好是1；-F是在文本中描述的药物中选择的，-X是在文本中描述的4个组-M，-T，-V和-Y中选择的。通式（I）的化合物是硝酸盐前药，可以在体内以受控和选择性的方式释放一氧化氮，而不会产生降压副作用，因此它们非常适用于制备用于预防和治疗肌肉骨骼，皮肤，呼吸，消化，泌尿和中枢神经系统的炎症，缺血，退行性和增生性疾病的药物。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• ANTIPYRETIC/ANALGESIC COMPOSITION
  申请人：Kowa Co., Ltd.

  公开号：EP2659889A1

  公开（公告）日：2013-11-06

  Provided is a stable pharmaceutical composition comprising ibuprofen and butylscopolamine bromide. The pharmaceutical composition comprises ibuprofen, butylscopolamine bromide, and a moisture-absorbing polymer.

  本发明提供了一种由布洛芬和溴化丁基东莨菪碱组成的稳定药物组合物。该药物组合物由布洛芬、溴化丁基东莨菪碱和吸湿聚合物组成。
• 医薬組成物
  申请人：大正製薬株式会社

  公开号：JP2003012514A

  公开（公告）日：2003-01-15

  (57)【要約】\n【解決課題】風邪等による喀痰症状に対する効果が増強された医薬組成物を提供する。\n【構成】（ａ）エプラジノン、オキセラジン及びこれらの塩から選ばれる塩の１種以上、並びに（ｂ）イソチペンジル、ジフェニルピラリン、ジフェンヒドラミン、ジフェテロール、トリプロリジン、トリペレナミン、トンジルアミン、フェネタジン、メトジラジン、カルビノキサミン、アリメマジン、メブヒドロリン、プロメタジン、クロルフェニラミン、イプロヘプチン及びこれらの塩から選ばれる１種以上を配合することを特徴とする医薬組成物。

  (57）[摘要]Јn[解决问题]提供一种对感冒等引起的痰液症状具有增强疗效的药物组合物。\n[结构]】(a) 一种或多种选自依普拉嗪酮、奥塞拉嗪及其盐类的盐，和 (b) 异硫苯咪唑、二苯基吡咯烷酮、苯海拉明、苯海拉明、曲普利啶、曲普利胺、通迪拉明、苯海拉明、甲氧地拉嗪、卡比诺沙明阿利美嗪、美布氢啉、异丙嗪、氯苯那敏、异丙吡汀和其中一种或多种盐类。
• Method and apparatus for dry granulation
  申请人：ATACAMA LABS OY

  公开号：US10265272B2

  公开（公告）日：2019-04-23

  A dry-granulation method for producing a tablet comprising (a) pharmaceutical active ingredient in an amount 50-90% w/w and (b) one or more excipients in an amount 10-50% w/w including at least a binder which comprises (i) preparing granules from a powder comprising a binder, a pharmaceutically active ingredient and optionally one or more other excipients or pharmaceutical active ingredients by a process characterized in that a compaction force is applied to the powder to produce a compacted mass comprising a mixture of fine particles and granules and separating and removing fine particles and/or small granules from the granules by entraining the fine particles and/or small granules in a gas stream in which the compacted mass flows, wherein the direction of the flow of the gas stream has a component which is contrary to that of the direction of flow of the compacted mass, and collecting the accepted granules (ii) blending the accepted granules with other components of the tablet in granular or fine powder form wherein in step (ii) at least one other component of the tablet formulation is in granular form and is prepared from a powder comprising said other component by a process characterized in that a compaction force is applied to the powder to produce a compacted mass comprising a mixture of fine particles and granules and separating and removing fine particles and/or small granules from the granules by entraining the fine particles and/or small granules in a gas stream in which the compacted mass flows, wherein the direction of the flow of the gas stream has a component which is contrary to that of the direction of flow of the compacted mass; and (iii) compressing the resultant blend to form a tablet; with the proviso that the tablet does not comprise (a) paracetamol, maize starch and microcrystalline cellulose in a ratio of 60:20:20 w/w, (b) acebutolol HCl and starch in a ratio of 90:10 w/w, (c) sodium valproate, hypromellose and maize starch in a ratio of 90:5:5 w/w, (d) ketoprofen and maize starch in a ratio of 50:50 w/w or (e) metformin HCl, microcrystalline cellulose and maize starch in a ratio of 80:14:6 w/w.

  一种生产片剂的干制粒方法，该片剂包含(a)重量百分比为 50-90%的药物活性成分和(b)重量百分比为 10-50%的一种或多种赋形剂，其中至少包括一种粘合剂，该方法包括(i)用包含粘合剂的粉末制备颗粒、(i) 从粉末中制备颗粒，该粉末包括粘合剂、药用活性成分和一种或多种其它辅料或药用活性成分，制备工艺的特点是对粉末施加压实力以产生由细小颗粒和颗粒混合物组成的压实物，并通过将细小颗粒和/或小颗粒夹带在压实物流动的气流中，将细小颗粒和/或小颗粒从颗粒中分离和去除，其中气流的流动方向与压实物的流动方向相反、收集所接受的颗粒 (ii) 将所接受的颗粒与颗粒状或细粉末状的片剂的其他成分混合，其中在步骤(ii)中，片剂配方中的至少一种其他成分为颗粒状，由包含所述其他成分的粉末制备而成，其特征在于，对粉末施加压实力以产生包含细颗粒和颗粒混合物的压实物，并通过在压实物流动的气流中夹带细颗粒和/或小颗粒，从颗粒中分离和去除细颗粒和/或小颗粒、其中，气流的流动方向与压实物的流动方向相反；(iii) 压缩所得混合物以形成片剂；但片剂不包括 (a) 对乙酰氨基酚、玉米淀粉和微晶纤维素的重量比为 60：20:20 w/w，(b)盐酸醋丁洛尔和淀粉的比例为 90:10 w/w，(c)丙戊酸钠、 低聚异麦芽糖和玉米淀粉的比例为 90:5:5 w/w，(d)酮洛芬和玉米淀粉的比例为 50:50 w/w，或(e)盐酸二甲双胍、微晶纤维素和玉米淀粉的比例为 80:14:6 w/w。